Aristo Bio-Tech and Lifescience Management
Management criteria checks 3/4
Aristo Bio-Tech and Lifescience's CEO is Narendra Barhat, appointed in Sep 2018, has a tenure of 6.25 years. directly owns 39% of the company’s shares, worth ₹366.39M. The average tenure of the management team and the board of directors is 6.3 years and 6.3 years respectively.
Key information
Narendra Barhat
Chief executive officer
₹4.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.3yrs |
| CEO ownership | 39.0% |
| Management average tenure | 6.3yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift Shares
Oct 30
Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?
Aug 22Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without Risk
Jun 29If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An Opportunity
Mar 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹59m |
| Jun 30 2024 | n/a | n/a | ₹49m |
| Mar 31 2024 | ₹5m | n/a | ₹39m |
| Dec 31 2023 | n/a | n/a | ₹37m |
| Sep 30 2023 | n/a | n/a | ₹36m |
| Jun 30 2023 | n/a | n/a | ₹36m |
| Mar 31 2023 | ₹5m | n/a | ₹36m |
| Mar 31 2022 | ₹5m | n/a | ₹14m |
| Mar 31 2021 | ₹5m | n/a | ₹11m |
| Mar 31 2020 | ₹5m | ₹5m | ₹10m |
Compensation vs Market: Narendra's total compensation ($USD56.52K) is above average for companies of similar size in the Indian market ($USD42.37K).
Compensation vs Earnings: Narendra's compensation has been consistent with company performance over the past year.
CEO
Narendra Barhat (69 yo)
6.3yrs
Tenure
₹4,802,200
Compensation
Mr. Narendra Singh Barhat serves as the Chairman & MD of Aristo Bio-Tech and Lifescience Limited since September 10, 2018. He served as a Director of Aristo Bio-Tech and Lifescience Limited since March 17,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 6.3yrs | ₹4.80m | 39% ₹ 366.4m | |
| Whole-Time Director & CFO | 6.3yrs | ₹2.70m | 10.58% ₹ 99.4m | |
| Executive Director | no data | ₹2.70m | 9.18% ₹ 86.3m | |
| Company Secretary & Compliance Officer | less than a year | no data | no data | |
| Vice President of Marketing & Sales | no data | no data | no data |
6.3yrs
Average Tenure
62yo
Average Age
Experienced Management: ARISTO's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 19.8yrs | ₹4.80m | 39% ₹ 366.4m | |
| Whole-Time Director & CFO | 6.3yrs | ₹2.70m | 10.58% ₹ 99.4m | |
| Executive Director | 19.8yrs | ₹2.70m | 9.18% ₹ 86.3m | |
| Non- Executive Independent Director | 6.3yrs | ₹125.00k | no data | |
| Non- Executive Independent Director | 2.8yrs | ₹100.00k | no data | |
| Additional Non-Executive Director | 2.8yrs | no data | no data |
6.3yrs
Average Tenure
65.5yo
Average Age
Experienced Board: ARISTO's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aristo Bio-Tech and Lifescience Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|